본문 바로가기
KERD
논문KCI 등재

내성 결핵균의 실태 및 치료

Current status of drug-resistant tuberculosis and its treatment

임재준
대한내과학회 (The Korean Association Of Internal Medicine)|2009.08|대한내과학회지 (The Korean Journal of Medicine)|제77권 제2호|pp. 152-156

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

결핵; 약제내성; 치료Tuberculosis; Drug resistance; Treatment
주제분류내과학

초록

Drug-resistant tuberculosis (TB), especially multidrug-resistant (MDR)-TB and extensively drug resistant (XDR)-TB, poses a serious threat to global health because it requires treatment for a long duration and frequent hospitalization, and results in a considerable number of mortalities. In South Korea, MDR is observed in 2.7% of newly diagnosed TB cases and in 14% of re-treatment cases. In addition, 5~20% of MDR-TB could be categorized as XDR-TB. Treatment regimen for MDR or XDR-TB should include 4~5 drugs susceptible to isolated tuberculous bacilli and should be maintained at least 18 months after culture conversion. Pertinent combination of anti-TB drugs and solid compliance are the basis of successful treatment for MDR and XDR-TB patients.

Abstract

Drug-resistant tuberculosis (TB), especially multidrug-resistant (MDR)-TB and extensively drug resistant (XDR)-TB, poses a serious threat to global health because it requires treatment for a long duration and frequent hospitalization, and results in a considerable number of mortalities. In South Korea, MDR is observed in 2.7% of newly diagnosed TB cases and in 14% of re-treatment cases. In addition, 5~20% of MDR-TB could be categorized as XDR-TB. Treatment regimen for MDR or XDR-TB should include 4~5 drugs susceptible to isolated tuberculous bacilli and should be maintained at least 18 months after culture conversion. Pertinent combination of anti-TB drugs and solid compliance are the basis of successful treatment for MDR and XDR-TB patients.

참고문헌 (39)

  1. WHO, "Global tuberculosis control: surveillance, planning, financing. World Health Organization", ~ (2007)
  2. Kim HJ, "Current Situation of Tuberculosis and Its Control in Korea", J Korean Med Assoc, 49, pp.762~772 (2006)
  3. Kang YA, "Cost of treatment for multidrug-resistant tuberculosis in South Korea", Respirology, 11, pp.793~798 (2006)
  4. Iseman MD, "Treatment of multidrug-resistant tuberculosis", N Engl J Med, 329, pp.784~791 (1993)
  5. Bai GH, "Trend of anti-tuberculosis drug resistance in Korea", Int J Tuberc Lung, 11, pp.571~576 (2007)
  6. Kim BJ, "The current status of multidrug- resistant tuberculosis in Korea", Tuber Lung Dis, 60, pp.404~411 (2006)
  7. Caminero JA, "Management of multidrug-resistant tuberculosis and patients in retreatment", Eur Respir J, 25, pp.928~936 (2005)
  8. Mukherjee JS, "Programmes and principles in treatment of multidrug-resistant tuberculosis", Lancet, 363, pp.474~481 (2004)
  9. Guidelines for the programmatic management of drug-resistant tuberculosis, "Stop TB department" (2008), World Health Organization
  10. Maus CE, "Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis", Antimicrob Agents Chemother, 49, pp.3192~3197 (2005)
  11. Sulochana S, "In vitro activity of fluoroquinolones against Mycobacterium tuberculosis", J Chemother, 17, pp.169~173 (2005)
  12. Williams DL, "Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis", Antimicrob Agents Chemother, 42, pp.1853~1857 (1998)
  13. Rastogi N, "In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages", Curr Microbiol, 33, pp.167~175 (1996)
  14. Pomerantz M, "Surgical management of resistant mycobacterial tuberculosis and other mycobacterial pulmonary infections", Ann Thorac Surg, 52, pp.1108~1111 (1991)
  15. Shiraishi Y, "Resectional surgery combined with chemotherapy remains the treatment of choice for multidrug-resistant tuberculosis", J Thorac Cardiovasc Surg, 128, pp.523~528 (2004)
  16. Park SK, "A retrospective study for the outcome of pulmonary resection in 49 patients with multidrug- resistant tuberculosis", Int J Tuberc Lung Dis, 6, pp.143~149 (2002)
  17. Pomerantz BJ, "Pulmonary resection for multi-drug resistant tuberculosis", J Thorac Cardiovasc Surg, 121, pp.448~453 (2001)
  18. Chiang CY, "Pulmonary resection in the treatment of patients with pulmonary multidrug- resistant tuberculosis in Taiwan", Int J Tuberc Lung Dis, 5, pp.272~277 (2001)
  19. Sung SW, "Surgery increased the chance of cure in multi-drug resistant pulmonary tuberculosis", Eur J Cardiothorac Surg, 16, pp.187~193 (1999)
  20. van Leuven M, "Pulmonary resection as an adjunct in the treatment of multiple drug-resistant tuberculosis", Ann Thorac Surg, 63, pp.1368~1372 (1997)
  21. Kir A, "Role of surgery in multi- drug-resistant tuberculosis: results of 27 cases", Eur J Cardiothorac Surg, 12, pp.531~534 (1997)
  22. Treasure RL, "Current role of surgery in Mycobacterium tuberculosis", Ann Thorac Surg, 59, pp.1405~1407 (1995)
  23. Kim HJ, "Prognostic factors for surgical resection in patients with multidrug-resistant tuberculosis", Eur Respir J, 28, pp.576~580 (2006)
  24. Kir A, "Adjuvant resectional surgery improves cure rates in multidrug-resistant tuberculosis", J Thorac Cardiovasc Surg, 131, pp.693~696 (2006)
  25. Laserson KF, "Speaking the same language: treatment outcome definitions for multidrug- resistant tuberculosis", Int J Tuberc Lung Dis, 9, pp.640~645 (2005)
  26. Kim DH, "Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis", Am J Respir Crit Care Med, 178, pp.1075~1082 (2008)
  27. Kwon YS, "Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis", Clin Infect Dis, 47, pp.496~502 (2008)
  28. Jeon CY, "Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital", Clin Infect Dis, 46, pp.42~49 (2008)
  29. Kim HR, "Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug- resistant tuberculosis", Clin Infect Dis, 45, pp.1290~1295 (2007)
  30. Gandhi NR, "Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa", Lancet, 368, pp.1575~1580 (2006)
  31. Kim DH, "Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis", Am J Respir Crit Care Med, 178, pp.1075~1082 (2008)
  32. Migliori GB, "Clinical and operational value of the extensively drug-resistant tuberculosis definition", Eur Respir J, 30, pp.623~626 (2007)
  33. Migliori GB, "Extensively drug-resistant tuberculosis is worse than multidrug-resistant tuberculosis: different methodology and settings, same results", Clin Infect Dis, 46, pp.958~959 (2008)
  34. Banerjee R, "Extensively drug-resistant tuberculosis in california, 1993-2006", Clin Infect Dis, 47, pp.450~457 (2008)
  35. Blaas SH, "Extensively drug resistant tuberculosis in a high income country: a report of four unrelated cases", BMC Infect Dis, 8, pp.60~ (2008)
  36. Mitnick CD, "Comprehensive treatment of extensively drug-resistant tuberculosis", N Engl J Med, 359, pp.563~574 (2008)
  37. Keshavjee S, "Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study", Lancet, 372, pp.1403~1409 (2008)
  38. Koh WJ, "Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis", J Antimicrob Chemother, 64, pp.388~391 (2009)
  39. Spigelman MK, "New tuberculosis therapeutics: a growing pipeline", J Infect Dis 196, 196, pp.S28~S34 (2007)

이 간행물의 다른 논문 (11건)

신종인플루엔자 A (H1N1) 대유행의 전망과 대책김우주pp. 139-142경피적 신생검 후 발생한 지연성 신 주위 혈종 1예류한승pp. 148-151대유행 신종인플루엔자 A (H1N1)의 역학, 임상 소견 및 치료김우주pp. 157-164뎅기열정문현pp. 165-170인슐린저항성의 발생기전최철수pp. 171-177
원문 보기